HDAC2 and prostate carcinoma: Chidamide, in contrast, selectively targets HDAC1, HDAC2, HDAC3, and HDAC10, aligning closely with the four HDAC isoforms most overexpressed in prostate cancer, making it a more biologically relevant candidate for mCRPC treatment [24].